OHCA 2019-06

May 29, 2019

RE: Change in Billing for Supprelin® LA

Dear Provider,

As authorized by OAC 317:30-5-77.2, effective July 1, 2019, the Oklahoma Health Care Authority (OHCA) will change the way Supprelin® LA for central precocious puberty is billed.

Supprelin® LA is only available through the medical benefit. The current billing code used is J9226. This code may change in the future based on guidance from the Centers for Medicare and Medicaid Services (CMS). It is the provider's responsibility to assure codes used for billing are up to date and accurate.

Supprelin® LA continues to require a prior authorization (PA). The specific PA requirements for Supprelin® LA are below and can be located on the OHCA website at www.okhca.org/pa in the “Diabetes/Endocrine” therapeutic category. Use the PA form PHARM-18, which can be found on the OHCA website at www.okhca.org/rxforms.

An FDA approved diagnosis of central precocious puberty is confirmed by submitting the following:

- Documentation of onset of symptoms <8 years of age in females and 9 years of age in males; AND
- Documentation that bone age is advanced 1 year beyond the chronological age; AND
- Lab assessment:
  - Documentation of abnormal basal gonadotropin levels; OR
  - Documentation of pubertal response to a gonadotropin-releasing hormone analog stimulation test; AND
- Approvals may be granted with documentation of failed trials of lower-tiered products or an FDA approved indication not covered by a lower-tiered product, such as Lupron Depot-Ped® and Triptodur®.

All medication PA requests are submitted to the Pharmacy Prior Authorization Unit at the fax number located at the bottom of the form. Do not submit the request to Medical Authorization Unit or via the provider portal.

If you have questions, please contact the Pharmacy Authorization Unit at (800) 522-0114, option 4.

Thank you for your continued service to our SoonerCare members.

Sincerely,

Rebecca Pasternik-Ikard
Chief Executive Officer